Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Cancer of unknown primary ranks in the top ten cancer presentations and has an extremely poor prognosis. Identification of the primary tumour and development of a tailored site-specific therapy could improve the survival of these patients. We examined the feasability of using DNA methylation profiles to determine the occult original cancer in cases of cancer of unknown primary.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Oct 2016

Volume: 17

Issue: 10

Affiliations

[1 ] Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

[2 ] Department of Pathology, Hospital Universitari Germans Trias i Pujol, C/ Ctra de Canyet s/n, Badalona, Barcelona, Catalonia, Spain.

[3 ] Medical Oncology, Catalan Institute of Oncology (ICO), University Hospital Germans Trias i Pujol, Badalona, Barcelona, Catalonia, Spain.

[4 ] Cardiothoracic and Vascular Department, Pneumology Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

[5 ] Institute for Cancer Research at Candiolo, Candiolo, Italy.

[6 ] IRBLleida Biobank, Lleida, Catalonia, Spain.

[7 ] Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, Lleida, Catalonia, Spain.

[8 ] Medical Oncology Service, Hospital Miguel Servet, Zaragoza, Spain.

[9 ] Medical Oncology Service, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.

[10 ] Medical Oncology, Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.

[11 ] Medical Oncology Service, Hospital Universitario Ramon y Cajal, Madrid, Spain.

[12 ] Biobanco Vasco, Hospital Universitario de Araba, Vitoria, Spain.

[13 ] Biobanco Vasco, Hospital Universitario de Basurto, Bilbao, Spain.

[14 ] Division of Epigenomics and Cancer Risk Factors at the German Cancer Research Center (DKFZ), Heidelberg, Germany.

[15 ] Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Catalonia, Spain.

[16 ] The Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; The Department of Pathology, University of Melbourne, Parkville, VIC, Australia.

[17 ] Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

[18 ] The Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Department of Pathology, University of Melbourne, Parkville, VIC, Australia.

[19 ] Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Catalonia, Spain; School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain; Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

[20 ] Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain; School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. Electronic address: mesteller@idibell.cat.

Article

Publisher Item ID: S1470-2045(16)30297-2

DOI: 10.1016/S1470-2045(16)30297-2

PubMed ID: 27575023

SO-VID: 2bd44c6f-8813-4126-8a94-96eac57187e1

History

Data availability:

Comments

Comment on this article

scite_

Cited by 199

See all cited by

- Version 1